AbbVie terminates collaboration with I-Mab for cancer drug development
TL;DR Summary
AbbVie is terminating its agreement with I-Mab regarding the development and commercialization of certain CD47 antibodies and products. This decision comes after AbbVie had previously opted out of part of the pact last year. The termination of the agreement is based on program discontinuation and AbbVie's strategic decision.
- AbbVie fully ditches I-Mab's CD47 drug after initial 2022 pullback from $1B+ bet Endpoints News
- AbbVie axes I-Mab pact to exit fast-thinning race for CD47 space FierceBiotech
- IMAB Regains Global Rights to Lemzoparlimab A New Chapter Begins Best Stocks
- AbbVie terminates deal with I-Mab to develop cancer drug Reuters
- IMAB and AbbVies Collaboration and the Termination of the Phase IB Trial for Lemzoparlimab Best Stocks
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
66%
142 → 48 words
Want the full story? Read the original article
Read on Endpoints News